Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

Purpose: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer.

Patients And Methods: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin.

Results: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .